Olfactomedin 4 (OLFM4) is highly expressed in gastrointestinal cancers and has an anti-apoptotic function. The roles of OLFM4 in tumor growth and metastasis and how it functions in these processes remain elusive. We investigated the function of OLFM4 in tumor growth and metastasis using B16F10 mouse melanoma cells as an experimental system. Our results showed that OLFM4 had no positive effect on cell viability or cell cycle progression in B16F10 cells. However, it significantly suppressed the tumorigenicity of B16F10 cells, i.e., intradermal primary tumor growth and lung metastasis. OLFM4 also suppressed the migration and invasion of B16F10 cells in vitro. For further insight into the mechanisms underlying OLFM4-mediated suppression of tumor progression, we examined the effect of OLFM4 on the expression of integrin and matrix metalloproteinase (MMP), both of which are involved in tumor progression. Overexpression of OLFM4 clearly reduced the expression levels of integrin α1, integrin α4, integrin α5, integrin α6, and MMP9. Moreover, forced expression of MMP9 attenuated the inhibitory activity of OLFM4 on migration and invasiveness. Our findings provide the experimental evidence that OLFM4 may function as a tumor suppressor and an anti-metastatic gene during tumor progression.
INTRODUCTION
OLFM4 (also known as hGC-1 or GW112) was initially cloned from human myeloblasts and classified as a member of the olfactomedin domain-containing protein family (Zhang et al., 2002) . OLFM4 expression is restricted to the gastrointestinal tract and bone marrow (Zhang et al., 2002) . OLFM4 has an anti-apoptotic property, and its expression is regulated by transcription factor NF-κB in gastric cancer cells (Kim et al., 2010; Zhang et al., 2004) . A growing number of studies indicate that the OLFM4 gene is strongly upregulated in gastrointestinal cancers, suggesting that OLFM4 is a reliable marker for several types of cancers, including gastric and cervical cancer (Grover et al., 2010; Oue et al., 2009; Yu et al., 2011a) .
OLFM4 enhances cell proliferation in some cases, while it suppresses proliferation in others Kobayashi et al., 2007) . When TRAMP-C1 mouse prostate cancer cells manipulated to overexpress OLFM4 were injected into mice, tumor growth was promoted by OLFM4 expression in vivo. However, OLFM4 showed anti-tumor growth and anti-metastatic effects in OLFM4-expressing PC-3 human prostate cancer cells, which seemed to be mediated by its ability to inhibit cell proliferation and abrogate stromal cell derived factor-1(SDF-1)-induced cell invasiveness Zhang et al., 2004) . On the other hand, OLFM4 overexpression did not alter proliferation in colon cancer cells (Liu et al., 2008) . Taken together, the effects of OLFM4 on the behavior of cancer cells seem to differ in a tissue-and/or cancer cell type-specific manner. More importantly, OLFM4 has been reported not to be strictly required for normal development and growth in mice, indicating that OLFM4 exerts its activity under specific pathological conditions such as cancers or infections by microorganisms (Liu et al., 2010) . Thus, it remains to be seen which role OLFM4 plays in cell cycle progression, tumor growth, and metastasis.
Metastasis is a complicated process that is dependent on the capacity of cancer cells to invade and migrate into adjoining tissues, and proliferate to form a tumor (Woodhouse et al., 1997) . Cancer cell invasion and migration are intimately associated with extracellular matrix (ECM) proteins such as matrix metalloproteinase (MMP) and integrin (Coussens et al., 2002; Egeblad and Werb, 2002; Felding-Habermann, 2003) . Notably, MMP1, MMP2, MMP9, and MMP14 have been implicated in the invasion and metastatic processes in several cancers (cous-sens et al., 2002; Egeblad and Werb, 2002) . It has also been reported that integrin expression is generally upregulated in highly metastatic melanomas (Hartstein et al., 1997; Moretti et al., 1993) . OLFM4 which is an ECM protein interacts with cell adhesion molecules to enhance cell attachment and cell spreading in 293T human embryonic kidney cells (Liu et al., 2006) . In contrast, migration and adhesion were decreased by OLFM4 overexpression in HT-29 human colon cancer cells (Liu et al., 2008) . To our knowledge, studies on cellular properties such as adhesion and metastasis have proposed several roles for OLFM4. However, controversial results have been obtained in different cellular contexts and thus the role of OLFM4 in tumor progression has not been definitively evaluated. Here, we used B16F10 mouse melanoma cells as an experimental system to directly explore the function of OLFM4 in tumor growth and metastasis and to gain better insight into the function of OLFM4 during tumor progression.
In this study, we showed that OLFM4 expression inhibited motility of B16F10 cells in vitro and their ability to form tumors as well as to form lung metastasis in vivo. We also provided evidence that the strong inhibitory activity of OLFM4 on tumor growth and metastasis of B16F10 cells is associated with downregulation of the integrin and MMP genes.
MATERIALS AND METHODS
Cell culture, construction of expression plasmids, and stable transfection B16F10 and SK-MEL-5 melanoma cell lines, which have been established from mouse melanoma and human melanoma respectively, were obtained from the American Type Culture Collection (USA) and grown under standard conditions. The full-length coding region of the OLFM4 was introduced into a plasmid pEGFP, which contains neomycin resistance cassette (Kim et al., 2010) . The expression plasmid for MMP9 was obtained from OriGene Technologies (USA). Lipofectamine 2000 (Invitrogen, USA) was used to transfect B16F10 cells with pEGFP or with human OLFM4 cDNA-containing pEGFP. Transfectant clones were selected with G418 (Invitrogen) and analyzed by reverse transcription polymerase chain reaction (RT-PCR) and immunoblotting.
RT-PCR and quantitative RT-PCR analysis
Total RNA was isolated using RiboEX (GeneAII, Korea), and 2 μg of total RNA were subjected to RT-PCR analysis using MMLV reverse transcriptase (Promega, USA). RT-PCR was performed using a Taq polymerase pre-mixture (Takara Bio, Japan), and the products were subjected to electrophoresis on 1% agarose gels. Quantitative real-time PCR was performed using a Rotor Gene 2000 (Corbett Research, USA) with SYBRGreen as a fluorescent dye (Qiagen, USA). The specificity of products generated by each set of primers was examined using gel electrophoresis and further confirmed by a melting curve analysis. The PCR primers used were 5′-GAATCTTCTACC TCATAACTTCCT-3′ and 5′-GCAACAACTGATAACTCATAAG T-3′ for OLFM4, 5′-TCACCCACACTGTGCCCATCTACGA-3′ and 5′-CAGCGG AACCGCTCATGCCAATGG-3′ for β-actin, 5′-GGTTCCTACTTTGGCAGTATT-3′ and 5′-AACCTTGTCTG ATTGAGAGCA-3′ for human integrin α1, 5′-AAGGGACCTT CAGGTGCA-3′ and 5′-TGTAGCCGGTGATTTACCAT-3′ for human integrin α3, 5′-GCTTCTCAGATCTGCTCGTG-3′ and 5′-GTCACTTCCAACG AGGTTTG-3′ for human integrin α4, 5′-TGCAGTGTGAGGCTGTGTACA-3′ and 5′-GTGGCCACCTG ACGCTCT-3′ for human integrin α5, 5′-TTGAATATACTGCTA ACCCCG-3′ and 5′-TCGAAACTGAACTCTTGAGGATAG-3′ for human integrin α6, 5′-TTGACAGCGACAAGAAGTGG-3′ and 5′-GCCATTCACGTCGTCCTTAT-3′ for human MMP9, and 5′-TCCCAGGAATTGGTGATAAAGTAGA-3′ and 5′-CTGGCATG ACGCGAACAATA-3′ for human MMP13. The primer sets for mouse integrin and MMP were prepared as described (Kidera et al., 2010) .
Flow cytometry for measuring cell cycle progression and apoptotic cells The 1 × 10 6 cells were harvested and washed with ice-cold PBS twice by centrifugation at 600 × g for 4 min. Cells were then fixed with ice-cold 70% ethanol at 4°C overnight. Fixed cells were washed twice and mixed with 500 μg/ml propidium iodide (PI) solution containing 50 μg/ml RNase at 37°C for 1 h. Flow cytometric analysis was performed using a FACS Calibur (Becton-Dickinson, USA). A 488 nm argon laser was used for excitation of fluorescent cells. Forward scatter and orthogonal side scatter were used to analyze cell size and granularity. An FL-2 detector was used and analyzed in the range of the FL-2 area (FL2-A) and width (FL2-W) to measure the different phases of the cell cycle and apoptotic-sub-G0 DNA content. All data were calculated and drawn using the FACS software, Cell Quest (Becton-Dickinson).
Preparation of cell extracts and immunoblot analysis
Whole cell extracts were prepared using RIPA buffer (SigmaAldrich, USA) supplemented with a protease inhibitor cocktail (Sigma-Aldrich). For immunoblot analysis, the protein samples were transferred to a polyvinylidene difluoride membrane following SDS-PAGE. The primary antibodies used in this study were monoclonal anti-α-tubulin antibody (Sigma-Aldrich), polyclonal anti-MMP9 antibody (Cell Signaling Technology, USA), and polyclonal anti-OLFM4 antibody (Lifespan Biosciences, USA). Binding of antibodies was detected by the SuperSignal system (Pierce, USA).
Measurement of cell proliferation and viability
Cellular proliferation and viability were determined by 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay (Roche Diagnostics, USA) using standard protocols. In brief, B16F10 cells were seeded with 200 μl of media in 96-well plates. After 12 h incubation, simvastatin was added at the indicated concentrations for 12 h. MTT solution (10 μl) was added to each well. After 4 h incubation at 37°C, culture supernatants were removed by centrifugation at 500 × g for 3 min. Crystallized violet product was dissolved by adding 0.1% isopropanol/HCl solution. Relative absorbance was measured at 570 nm using a Model 550 ELISA reader (Bio-Rad, USA). Simvastatin (MSD, Korea) was reconstituted in 100% ethanol and stored at -20°C.
Cell migration and invasion assays
Migration assays were performed using Transwell migration chambers (8 μm pore size, Millipore, USA). The 1 × 10 4 B16F10 cells, stably transfected with a plasmid encoding OLFM4, were plated in the top chamber well (apical side) of a non-coated membrane (24-well insert). For invasion assays, 1 × 10 4 cells were plated in the top chamber well of a Matrigel-coated (80 μg/ml, BD Bioscience, USA) membrane (24-well insert). After 24 h of migration, cells remaining on the apical side of each insert were removed with a cotton swab. The cells that had migrated to the basal side of the membrane were fixed with methanol, and then stained with Giemsa (Sigma). The cells stained with trypan blue were counted.
Tumor growth and metastasis in mice
The 2 × 10 5 B16F10 cells were injected subcutaneously into the left thigh of 6-week-old C57BL/6 female mice, and then the primary tumor size was measured for 19 days at 3 day intervals. Tumor volumes were calculated using the formula V = (W 2 × L)/2, where V is the tumor volume, W is the width, and L is the length. The 2 × 10 5 B16F10 cells were injected into the lateral tail vein of 6-week-old C57BL/6 female mice to identify lung metastasis. Two or three weeks later, mice were sacrificed and lungs were collected for counting metastatic nodules. The graph shows the total number of metastatic nodules per lung (Fig. 2B ). All animal-related procedures were approved by the Institutional Committee for Animal Care and Usage, Chungnam National University.
RESULTS
OLFM4 suppresses tumor growth and metastasis OLFM4 is highly expressed in gastrointestinal cancers and has a potent anti-apoptotic property (Kim et al., 2010; Luo et al., 2011; Zhang et al., 2004) . To study the effect of OLFM4 expression on the metastatic potential of mouse tumor cells, we first created stable transfectants carrying either OLFM4 expression vector or the control vector in B16F10 mouse melanoma cells, which are highly metastatic and do not express an endogenous OLFM4 gene. The resulting B16F10 clones that stably transfected with the OLFM4 vector (Clone 1 and Clone 2) showed strong OLFM4 expression at both the mRNA (Fig.  1A ) and protein level (Fig. 1B) . B16F10 transfected with the control vector (Control) did not express a detectable level of OLFM4, as confirmed by RT-PCR and immunoblot analysis. We were able to visually confirm the cytoplasmic localization of the OLFM4 protein in B16F10 cells (data not shown). Next, we subcutaneously injected the OLFM4-expressing B16F10 clones into the left thighs of mice and measured the primary tumor growth at different time points to determine whether OLFM4 expression contributes to tumor growth in vivo (Fig. 1C) . We found that significantly smaller tumor masses developed in mice injected with OLFM4-expressing B16F10 clones when compared to those injected with control vector-expressing cells. These observations strongly suggest the inhibitory activity of OLFM4 expression on the tumor-forming ability of B16F10 cells (Figs. 1C and 1D) .
We then investigated the potential effect of OLFM4 expression on the metastatic ability of melanoma cells. Either OLFM4-expressing B16F10 clone 1 or control vector-expressing cells were injected into the mouse lateral tail vein, and the number of black nodules representing lung metastases were quantified on days 14 and 21 post injection (Fig. 2) . When mice were injected with cells expressing the control vector, the B16F10 melanoma cells were readily metastasized into the lung, resulting in the formation of numerous lung metastatic nodules (45 ± 7 and 151 ± 42 on days 14 and 21, respectively) (Fig. 2B) . In contrast, mice injected with OLFM4-expressing B16F10 clone 1 displayed significantly fewer lung metastatic nodules (16 ± 7 and 8 ± 6 on 14 and 21 days post injection, respectively). Similar results were obtained with the OLFM4-expressing clone 2 (data not shown). These results indicate that OLFM4 expression causes a significant retardation in tumor metastasis.
OLFM4 has no effect on the progression of melanoma cell cycle Previous studies have shown that OLFM4 confers an antiapoptotic property on cancer cells, thereby making cells more resistant to anti-cancer drugs (Kim et al., 2010) . However, our observations suggested an opposing activity of OLFM4 for growth of the primary tumor and metastasis. The inhibitory effect of OLFM4 on tumor growth and metastasis could be due to its influence on the cell cycle or cell growth. Therefore, MTT assay was employed to examine the effect of OLFM4 expression on cell growth in OLFM4-expressing B16F10 clone 1 and control vector-expressing cells. The data clearly indicated that cellular proliferation was not altered by OLFM4 expression (Fig.  3A) . We further examined whether progression of the cell cycle was affected by OLFM4 expression in these cells. Flow cytometric analysis demonstrated that OLFM4 expression did not alter the percentage of cells in each phase when compared to the cells expressing control vector (Figs. 3B and 3C ).
To address if endogenous expression of OLFM4 plays a role in cell cycle progression, we employed shRNA to knockdown OLFM4 mRNA in AGS human gastric cancer cells which express endogenous OLFM4 gene abundantly (Kim et al., 2010) . Both OLFM4 mRNA and protein levels were decreased markedly in the OLFM4-knockdown cells (OLFM4-Kd), when compared to the control vector-expressing cells ( Supplementary   Figs. 1A and 1B) . Nevertheless, the cellular proliferation and percent of cell cycle progression were not significantly altered ( Supplementary Figs. 1C-1E ), confirming that OLFM4 has no significant effect on cell cycle progression. Simvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor that also inhibits cell growth and induces apoptosis in different types of cancer cells, including melanoma (Bardou et al., 2010; Cho et al., 2008; Favero et al., 2010; Kidera et al., 2010) . Because OLFM4 expression resulted in reduced tumor size and metastasis, we hypothesized that B16F10 cells expressing OLFM4 would be more vulnerable to simvastatin treatment compared to 
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Data are represented as mean ± SD (n = 3). *P < 0.001, **P < 0.005 (Student's t-test).
cells expressing control vector only. Under normal culture conditions, OLFM4 expression did not affect B16F10 cell viability (Fig. 3D, 0 µm simvastatin) . When B16F10 cells expressing the control vector were treated with increasing concentrations of simvastatin, concomitant drops in the percent of cell viability were observed (Fig. 3D) . In contrast, simvastatin-induced apoptosis was significantly attenuated by OLFM4 expression (Fig.  3E ). Although this result was against our hypothesis, it agreed well with the finding that OLFM4 has anti-apoptotic properties upon simvastatin treatment in gastric cancer cells (Supplementary Figs. 1F-1H ). Taken together, these results demonstrate that the anti-tumor growth and anti-metastatic properties of OLFM4 were not due to a general decrease in cell viability or altered cell cycle progression.
The inhibitory effect of OLFM4 on tumor growth and metastasis is associated with downregulation of integrin and MMP genes The observation that OLFM4 did not change the cell cycle or viability prompted us to investigate whether the inhibitory effect of OLFM4 on tumor growth and metastasis could be due to decreased invasiveness or an altered ability of cells to migrate, two critical processes which occur during tumor growth and metastasis. To address this possibility, we seeded B16F10 cells expressing either OLFM4 (Clone 1) or the control vector onto Transwell plates with or without a Matrigel coating and performed a migration assay and an invasion assay, respectively. B16F10 cells expressing the control vector easily migrated and invaded through the pores (Figs. 4B and 4D) . Interestingly, OLFM4 expression resulted in a > 90% reduction in the number of cells that migrated or invaded through the pores (475 ± 72 vs. 32 ± 6 and 65 ± 17 vs. 2 ± 2, respectively; Figs. 4B and 4D). These results show that OLFM4 expression affects migratory behavior and the invasiveness of B16F10 melanoma cells without influencing their survival. Cell-adhesion receptor integrins are key players in cancer cell metastasis, whereas MMPs are crucial in cancer cell invasiveness (Curran and Murray, 2000; Felding-Habermann, 2003; Munshi and Stack, 2006) . Altered migratory behavior and invasiveness of OLFM4-expressing cells prompted us to examine The mRNA quantification using real-time PCR showed that OLFM4 expression substantially downregulated MMP9 as well as integrin α1, 4, 5, and 6 mRNA levels compared to levels found in the control. (B) Expression levels of integrin α6 and MMP9 were decreased in OLFM4-expressing SK-MEL-5 human melanoma cells. The mRNA levels were normalized using β-actin as an internal control, and the ratios of mRNA levels in the OLFM4-expressing cells to the control were calculated.
A B C Fig. 6 . Re-expression of MMP9 attenuates the inhibitory effect of OLFM4 on migration and invasiveness. (A) MMP9 expression construct was transfected into OLFM4-expressing B16F10 clone 1. Cell lysates were analyzed by immunoblotting using anti-MMP9 antibody. α-Tubulin was used as a protein loading control. (B) Representative photographs show results of migration assay (upper panels) and invasion assay (lower panels) with control B16F10 cells, OLFM4-expressing B16F10 clone 1, or MMP9 re-expressing clone 1. (C) Results of migration and invasion assays were quantified. Data are represented as mean ± SD (n = 3). *P < 0.001, **P < 0.005 (Student's t-test).
the expression of integrins and MMPs in these cells. Indeed, when we looked at expression of integrin genes, OLFM4-expressing B16F10 clone 1 showed substantially reduced levels of integrin α1, α4, α5, and α6 mRNA relative to the levels found in control vector-expressing cells (Fig. 5A) . Similarly, OLFM4-expressing cells had a significantly lower level of MMP9 mRNA compared to the level found in control vector-expressing cells (Fig. 5A) . MMP14 mRNA levels, however, were not altered by overexpression of OLFM4. Among the genes listed above, the most significant reduction of MMP9 expression was further validated in SK-MEL-5 human melanoma cells (Fig. 5B) . In this case, however, integrin α1, 4, and 5 mRNA levels were not found to be affected by OLFM4 overexpression. This result prompted us to explore whether forced expression of MMP9 is able to attenuate the inhibitory effect of OLFM4 on migration and invasiveness. OLFM4-expressing B16F10 clone 1 was transfected with the expression plasmid for MMP9 or the control vector. After 24 h of transfection, there was a marked decrease in the expression of MMP9 in OLFM4-expressing B16F10 clone 1, as confirmed by immunoblot ana-lysis (Fig. 6A) . Strikingly, forced re-expression of MMP9 in this cell partially rescued the inhibitory effect of OLFM4 on migration and invasiveness (Fig.  6C) . These results suggest that the inhibitory activity of OLFM4 on tumor growth and metastasis may be mediated via downregulation of MMP9.
DISCUSSION
The OLFM4 expression level is highly upregulated in several cancers, including breast, colon, gastric, lung, and pancreatic cancer Oue et al., 2009) . Our previous report suggested that OLFM4 has an anti-apoptotic property in gastric cancer cells (Kim et al., 2010) . Moreover, OLFM4 expression is positively correlated with differentiation and progression of gastric, colon, and cervical cancers (Liu et al., 2007; Yu et al., 2011a; 2011b) . Of interest, OLFM4 expression decreases in the invasive region of colon cancer, suggesting the possibility that the function of OLFM4 is associated with the metastatic invasion process (Liu et al., 2008) . To determine how OLFM4 is associated with metastasis, we utilized the B16F10 mouse melanoma cell line as a model system. Our results strongly suggest that OLFM4 might play a role in the suppression of tumor metastasis. Our observations largely agree with those of Chen et al. who reported that OLFM4 has suppressive activity during tumor growth in PC-3 prostate cancer cells . However, it was unexpected to find that OLFM4 suppressed tumor growth and metastasis, because OLFM4 has an anti-apoptotic property in gastric cancer cells in vitro (Kim et al., 2010) . In fact, the anti-apoptotic property of OLFM4 was also demonstrated in the B16F10 melanoma cells in this study (Fig. 3) . These observations suggest the possibility that OLFM4 may be involved in two different aspects of tumor progression. That is, although OLFM4 could enhance the survival rate of cancer cells in vitro, it might also suppress the advancement of metastasis in vivo. OLFM4 was originally identified from human myeloid cells, and its expression is specific to the myeloid lineage among peripheral blood mononuclear cells (Zhang et al., 2002) . Also, OLFM4 protein is secreted because it is an ECM glycoprotein (Oue et al., 2009 ). It has recently been reported that OLFM4 is involved in innate immunity against Helicobacter pylori infection (Liu et al., 2010) . Our study does not exclude the potential contribution of immune responses. The activity of OLFM4 in an in vitro system may be different from that in the presence of immune responses in vivo. This still needs to be determined.
B16F10 cells have been widely used as a model system to study cancer metastasis (Park et al., 2012) . Therefore, we employed this system to reveal the role of OLFM4 during tumor progression. Metastasis is a multistep process in which metastatic cancer cells must invade the stroma, intravasate, survive in circulation, attach, extravasate, invade the matrix, and proliferate in the target organ (Woodhouse et al., 1997) . In the present study, we demonstrated that OLFM4 suppresses tumor progression by inhibiting migration and invasion. Our data indicate that OLFM4 indeed affects several steps during lung metastatic processes. First, we showed that the expression of MMP9, which has been implicated in the metastatic process of invasion, decreases significantly in OLFM4-expressing B16F10 cells compared to the control cells. This result provides a potential explanation concerning how OLFM4 could suppress metastasis (Curran and Murray, 2000) . Consistent with this result, migration and invasion of B16F10 cells were decreased following OLFM4 expression. Furthermore, forced re-expression of MMP9 rescues the inhibitory effect of OLFM4 on migration and invasiveness. This is probably due to the fact that MMP activity is essential for migration and invasion during tumor evolution. In addition, OLFM4 induced an overall downregulation of integrin genes except for integrin α3. Integrin genes are a family of cell adhesion receptors, which are involved in each step of the metastatic cascade (Felding-Habermann, 2003; Munshi and Stack, 2006) . We provide evidence that suppression of tumor growth and invasion via OLFM4 expression might be associated with the downregulation of integrin and MMP genes. However, the inhibitory activity of OLFM4 in tumor growth and metastasis may not be limited to these genes.
Taken together, this study has demonstrated the anti-tumor and anti-metastatic activities of OLFM4 in B16F10 mouse melanoma cells, which are associated with downregulation of integrin and MMP gene expression. Although the detailed molecular mechanism of OLFM4 activity remains to be elucidated, OLFM4 may represent a potential therapeutic candidate for cancer.
Note: Supplementary information is available on the Molecules and Cells website (www.molcells.org).
